Lipitor Ad Suggests Lower Rhabdomyolysis Risk Than Other Statins, FDA Says
Executive Summary
A direct-to-consumer print ad for Pfizer's Lipitor suggests the product is not associated with the same risk of rhabdomyolysis as other statins, a letter from FDA's Division of Drug Marketing, Advertising & Communications maintains
You may also be interested in...
Baycol Withdrawal Gives Boost To Pravachol; Will Crestor NDA Be Affected?
Bristol-Myers Squibb's Pravachol is gaining share in the retail market in the early days following the withdrawal of Bayer's Baycol, prescription tracking data from ArcLight indicate.
Pfizer changes Lipitor ad
FDA objects to eight-page journal ad for Pfizer's Lipitor (atorvastatin) in July 12 letter on the grounds that it implies a claim for the off-label indication of prevention of coronary heart disease. Ad depicts "apparent candidates for Lipitor" wearing nametags saying they have hyperlipidemia and another coronary heart disease risk factor, agency notes. The ad "creates an overwhelming impression that Lipitor is indicated to reduce the risk of developing coronary heart disease," FDA concludes. Atorvastatin is not approved for that claim. Pfizer discontinued the ad and plans to introduce a new journal ad
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011